Vol. 9, Issue 3 (2020)
Doravirine: A review
M Prashanthi Evangelin, Dr. P Prem Kumar, B Gopi Krishna, S Yashita Raga and SVS Gopi Raju
HIV-1 patients with failure regimen due to resistant mutant’s leads to the development of third new antiviral agent called Doravirine to treat infection in 2018 which was metabolized through CYP3A pathway. It is a highly specific and unique NNRTI (non-nucleoside reverse transcriptase inhibitor) with high in vitro activity against wild type virus and mutant viruses containing NNRTI resistance mutations (K103N, Y181C, G190A, E138K, and K103N/Y181c). Doravirine shows excellence aqueous solubility when compared with second generation NNRTIs so, it has more chances for further development and this promising novel drug had preferred for the treatment of AIDS, which is currently in its phase III clinical development. It shows strong in vivo antiviral activity with good tolerability and it shows adverse effects like nausea, dizziness, vomiting, abdominal pain and abnormal dreams to the some extent. The present literature reviews about the different analytical methods of Doravirine.
How to cite this article:
M Prashanthi Evangelin, Dr. P Prem Kumar, B Gopi Krishna, S Yashita Raga, SVS Gopi Raju. Doravirine: A review. Pharma Innovation 2020;9(3):67-69.